Search for a trial

Levothyroxine for euthyroid women with recurrent miscarriage and positive TPO antibodies: a randomized controlled trial

First objective: To assess improvement in live birth rate after levothyroxine supplementation. Secondary objective: 1) to test the hypothesis that levothyroxine lowers the risk for miscarriage and preterm birth 2) to test the hypothesis that…

Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial.

1. Normalization of the abnormal serum TH parameters and thereby improving the clinical condition of the AHDS patients2. Observation of changes in cognitive and motor function.

A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

The purpose of this study is to find out if patients with locally advanced/metastatic Radioactive Iodine-refractory (RAI) thyroid cancer (papillary, follicular or Hurthle cell carcinoma), will benefit from sorafenib treatment compared to patients…

A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)

The primary objective is to investigate the efficacy, safety and tolerability of RV 001 (a fully human anti-IGF-1R antibody) administered q3W for 6 months, in comparison to placebo, in the treatment of patients suffering from active TED.Secondary…

A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with eitherc differentiated and medullary thyroid carcinoma progressing after first line therapy.

The primary objective is to explore the efficacy of nintedanib (as measured by progression free survival) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.

Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II

This study has been transitioned to CTIS with ID 2024-516123-13-00 check the CTIS register for the current data. Part I:Primary Objective: Evaluate the effects of tiratricol on neurodevelopment in young MCT8 deficiency patients, as measured by the…

An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored lenvatinib trials

The primary objective is to assess long-term safety of study drug(s) in subjects who are enrolled in Eisai-sponsored lenvatinib studies.

Ultrasound-guided Radiofrequency Ablation versus radioactive iodine as Treatment for Hyperthyroidism caused by Solitary Autonomous Thyroid Nodules

This study has been transitioned to CTIS with ID 2024-515602-34-01 check the CTIS register for the current data. To assess which treatment leads to the best patient outcome on the short term (1 year) and the long term (5 years)

A national randomized placebo-controlled double-blind multicenter trial of
LT4/LT3 combination therapy in patients with autoimmune
hypothyroidism.

This study has been transitioned to CTIS with ID 2024-513883-24-00 check the CTIS register for the current data. Primary Objective: To investigate the effects of LT4/LT3 combination therapy compared to LT4 monotherapy on tiredness in those patients…

Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Placebo-controlled Study

This study has been transitioned to CTIS with ID 2024-516124-34-00 check the CTIS register for the current data. Primary Objective:• To evaluate the effects of withdrawal of tiratricol treatment (placebo group) on serum total triiodothyronine (T3)…

Inhibition of salivary glands to reduce uptake of radioactive Iodine

Primary: to determine if inhibition with GPB can provide a significant (>30%) reduction in the accumulation of orally administered Iodine-123 in salivary glands, measured at 4h after administraion. Secondary: to determine if a reduction at 4h…